Phase I/II Trial of Iberdomide in Relapsed Neuroblastoma Shows Potential Efficacy
A phase I/II trial is investigating the safety and efficacy of iberdomide combined with chemoimmunotherapy in patients with relapsed or refractory neuroblastoma.
Phase I
National Cancer Institute
Status
Active
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The ongoing phase I/II trial of iberdomide in relapsed neuroblastoma presents a significant opportunity for innovation in treatment protocols. A successful outcome could redefine standard care and enhance competitive positioning in the oncology market for neuroblastoma therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for safety and efficacy outcomes, as well as any regulatory developments related to iberdomide.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.